Tina Flatau
Direttore/Membro del Consiglio presso Sixfold Bioscience, Inc.
Profilo
Tina Flatau is currently a Director at Sixfold Bioscience, Inc. She previously worked as the Managing Director at MedAnnex Ltd.
and as the Vice President-Alliances & Project Management at Prosensa Holding NV.
Posizioni attive di Tina Flatau
| Società | Posizione | Inizio |
|---|---|---|
Sixfold Bioscience, Inc.
 Sixfold Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sixfold Bioscience Ltd., Sixfold Bioscience, Inc. operates as a biotechnology company that develops next-generation in vivo delivery systems for RNA therapeutics. The company is based in Walnut, CA. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Tina Flatau
| Società | Posizione | Fine |
|---|---|---|
MedAnnex Ltd.
 MedAnnex Ltd. Miscellaneous Commercial ServicesCommercial Services MedAnnex Ltd. operates preclinical-stage biotechnology company. It develops approaches to treating autoimmune diseases and other medical conditions. The company was founded by Christopher Barry Wood and Hugh Stephen Griffith in 2009 and is headquartered in Edinburgh, the United Kingdom. | Amministratore Delegato | 01/03/2019 |
| PROSENSA HOLDING NV | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 3 |
|---|---|
Prosensa Holding NV
 Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
MedAnnex Ltd.
MedAnnex Ltd. Miscellaneous Commercial ServicesCommercial Services MedAnnex Ltd. operates preclinical-stage biotechnology company. It develops approaches to treating autoimmune diseases and other medical conditions. The company was founded by Christopher Barry Wood and Hugh Stephen Griffith in 2009 and is headquartered in Edinburgh, the United Kingdom. | Commercial Services |
Sixfold Bioscience, Inc.
Sixfold Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sixfold Bioscience Ltd., Sixfold Bioscience, Inc. operates as a biotechnology company that develops next-generation in vivo delivery systems for RNA therapeutics. The company is based in Walnut, CA. | Commercial Services |
- Borsa valori
- Insiders
- Tina Flatau
